Sustainable Healthcare


Access to Medicines and Diagnostics in Australia


Our aim is for every person who needs our diagnostic tests to be able to benefit from them.


Ensuring patients have access to healthcare is a shared responsibility requiring many stakeholders to work together. The Medicare Benefits Schedule (MBS) has delivered broad access to diagnostic tests for generations of Australians, and Roche recognises the importance of their roles. Roche supports the continued reform of these schemes to ensure the value of each medicine and diagnostic test is assessed on a broad range of factors, such as improved health outcomes, productivity gains, healthcare efficiency and addressing an unmet need.


We believe that continued investment in the MBS needs to be sustainable, and growth should be in line with the economic resources of Australia and the needs of an ageing population.


We are focused on increasing broad access to medicines and diagnostic tests, as well as providing support to patients in the following areas:

  • disease awareness for patients
  • medical education for healthcare professionals
  • gaining regulatory approval through the Therapeutics Goods Administration (TGA)
  • reducing costs for patients for our diagnostic tests via the Medicare Benefits Schedule (MBS)


Our innovative medicines and diagnostic tests are only meaningful if they reach the people who need them when they need them – no matter where they live.


Severin Schwan
CEO of Roche Group

How is Roche Diagnostics Contributing to Sustainable Healthcare?